Unravel Biosciences

3:45 PM - 4:00 PM (EDT), Monday, June 5, 2023 ・ Session Room 104C
Unravel Biosciences is the first rapid prototyping therapeutics company leveraging AI models of patient RNA networks and seamless clinical validation to discover and clinically validate novel targets for neurological and non-neurological disorders, generating highly effective therapeutics. Unravel is validating a new target for Rett syndrome in the clinic while developing a new small molecule asset that has already demonstrated preclinical efficacy, a growing asset pipeline across indications, and initiating multiple therapeutics discovery partnerships.
Not Provided
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
RVL002 for Rett syndrome
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
President and CEO
Unravel Biosciences